Boehringer selects Vectron’s expression technology platform

The companies have signed a non-exclusive license deal, which follows a joint feasibility study.

Under the study, Vectron’s genetic elements were tested for high-yield, soluble production of a protein of interest to Boehringer Ingelheim in Escherichia coli.

Boehringer has the right to use Vectron’s technology for production of biopharmaceutical products from their own in-house pipeline.

The technology can also be utilized as part of the Boehringer’s BioXcellence offerings in contract manufacturing.

Boehringer Ingelheim head of global technology and innovation management for biopharmaceuticals Jan Schöning said: "We at Boehringer Ingelheim are permanently developing and scouting novel and innovative technologies to further improve our strong microbial production platform.

"We believe that there is a high synergy of the Vectron Biosolutions’ technology with Boehringer Ingelheim’s own proprietary E. coli based expression systems.

Vectron Biosolutions CEO Trond Erik Vee Aune said: "With Boehringer Ingelheim’s strong position in the industry, we anticipate that many future biopharmaceutical proteins will be produced using our technology."

Boehringer’s BioXcellence provides contract development and manufacturing services to the biopharmaceutical industry.